Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Cash from Investing Activities (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Cash from Investing Activities for 4 consecutive years, with $47.2 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Cash from Investing Activities rose 424.71% year-over-year to $47.2 million, compared with a TTM value of -$38.0 million through Dec 2023, down 70.56%, and an annual FY2024 reading of -$12.4 million, up 67.33% over the prior year.
  • Cash from Investing Activities was $47.2 million for Q4 2023 at Terns Pharmaceuticals, up from -$22.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $47.2 million in Q4 2023 and bottomed at -$96.8 million in Q1 2021.
  • Average Cash from Investing Activities over 4 years is -$10.8 million, with a median of -$671000.0 recorded in 2020.
  • Peak annual rise in Cash from Investing Activities hit 88960.0% in 2021, while the deepest fall reached 20392.16% in 2021.
  • Year by year, Cash from Investing Activities stood at -$47000.0 in 2020, then tumbled by 13561.7% to -$6.4 million in 2021, then crashed by 126.54% to -$14.5 million in 2022, then surged by 424.71% to $47.2 million in 2023.
  • Business Quant data shows Cash from Investing Activities for TERN at $47.2 million in Q4 2023, -$22.3 million in Q3 2023, and -$90.8 million in Q2 2023.